Mark Litton
2023 - Athira Pharma
In 2023, Mark Litton earned a total compensation of $2.3M as President and Chief Executive Officer at Athira Pharma, a 40% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $297,619 |
|---|---|
| Option Awards | $1,378,860 |
| Salary | $585,000 |
| Other | $85 |
| Total | $2,261,564 |
Litton received $1.4M in option awards, accounting for 61% of the total pay in 2023.
Litton also received $297.6K in non-equity incentive plan, $585K in salary and $85 in other compensation.
Rankings
In 2023, Mark Litton's compensation ranked 451st out of 3,006 executives tracked by ExecPay. In other words, Litton earned more than 85.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 451 out of 3,006 | 85th |
Division Manufacturing | 258 out of 1,650 | 84th |
Major group Chemicals And Allied Products | 178 out of 918 | 81st |
Industry group Drugs | 175 out of 881 | 80th |
Industry Biological Products, Except Diagnostic Substances | 63 out of 213 | 70th |
Source: SEC filing on April 9, 2024.
Litton's colleagues
We found two more compensation records of executives who worked with Mark Litton at Athira Pharma in 2023.